Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totaling 2,350 shares, an increase of 351.9% from the August 15th total of 520 shares. Based on an average trading volume of 521 shares, the short-interest ratio is currently 4.5 days.
Silence Therapeutics Price Performance
Silence Therapeutics stock opened at $4.00 on Friday. Silence Therapeutics has a one year low of $1.06 and a one year high of $5.99. The business has a fifty day moving average price of $3.05 and a 200-day moving average price of $2.28.
About Silence Therapeutics
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
- American Eagle Goes on Sale: Is It Time to Buy?
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
